Equities
  • Price (EUR)0.717
  • Today's Change0.017 / 2.37%
  • Shares traded0.00
  • 1 Year change+88.73%
  • Beta0.8697
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Key statistics

On Tuesday, Sino Biopharmaceutical Ltd (SMZ1:STU) closed at 0.717, -27.75% below its 52-week high of 0.9924, set on Sep 05, 2025.
52-week range
Today
0.3661Feb 11 20250.9924Sep 05 2025
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open0.7182
High0.7286
Low0.712
Bid0.717
Offer0.725
Previous close0.7004
Average volume37.09k
Shares outstanding18.76bn
Free float10.55bn
P/E (TTM)27.14
Market cap123.82bn HKD
EPS (TTM)0.2432
HKD
Annual div (ADY)0.0099
EUR
Annual div yield (ADY)1.41%
Div ex-dateAug 29 2025
Div pay-dateSep 23 2025
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.